Organisation paid for research Program year 2025 Source: CMS Open Payments

Bluegrass Epilepsy Research LLC

Neither a doctor nor a teaching hospital

Research payments

$25,339

13 payments

Through program year 2025, Bluegrass Epilepsy Research LLC is reported as receiving $25,339 in research payments, across 13 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$12,927	4
2024	Research	$2,383	3
2023	Research	$10,029	6

Breakdown

Who paid Research payments · program years 2023–2025

SK Life Science, Inc. $11,874 5 payments
Takeda Pharmaceuticals U.S.A., Inc. $7,826 6 payments
AbbVie, Inc. $5,639 2 payments

Studies the money was for Research payments · program years 2023–2025

A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy $7,826 6 payments
Ykp509c003 $6,399 4 payments
Ykp3089c049 $5,475 1 payment
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures $3,000 1 payment
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures $2,639 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.